Pharmala Biotech Holdings Inc.
Pharmala Biotech Holdings Inc.
CSE Index:
Currency:
Pharmala is focused on manufacture of Active Pharmaceutical Ingredients, of the Substituted methylenedioxy- phenethylamines class (“MDXX”), including 3,4-Methylenedioxymethamphetamine (“MDMA”). Pharmala also intends to undertake development of novel formulations of MDMA and the MDXX class of compounds, as well as developing novel drug delivery pathways for these molecules.
Pharmala Biotech Holdings Inc. (MDMA)
SEDAR Information
Company Info
Address
82 Richmond St.
Toronto, ON M5C 1P1
CanadaPhone
1-855-444-6362Email
outreach@pharmala.caWebsite
https://pharmala.ca/Listing date
Tuesday, January 11, 2022Transfer Agent
Marrelli Trust Company LimitedEmail
investors@pharmala.caAuditor
Clearhouse LLPCapitalization
Issued & Outstanding:
91124217Reserved for Issuance:
13923331Company Officers
Nicholas Kadysh , President, Chief Executive Officer and Director
Carmelo Marrelli , Chief Financial Officer and Corporate Secretary
Shane Morris , Chief Operating Officer
News Releases
Bulletins
10/01/2022
2022-0110 - New Listing - Pharmala Biotech Holdings Inc. (MDMA)
le 10 janvier/January 2022
The common shares of Pharmala Biotech Holdings Inc. have been approved for listing on the CSE.
Listing and disclosure documents will be available at www.thecse.com on the trading date.
